Abstract:Insulin-like growth factors (lGFs) are potent mitogens for breast cancer cells. Although IGF-binding proteins (IGFBPs) are known to regulate access of IGFs to IGF receptors, their precise biological actions are poorly defined. We observed that the potent antiestrogen ICI 182780 (ICI) increased IGFBP-5 mRNA by 2-3-fold in 9,1O-dimethyl-1 ,2-benzanthracene-induced mammary tumors in vivo. In vitro studies showed that growth inhibition of MCF-7 human breast cancer cells induced by ICI was associated with increased transcription of the IGFBP-5 gene, increased IGFBP-5 mRNA abundance, and increased IGFBP-5 protein accumulation in the conditioned medium. Growth stimulation following estradiol exposure was associated with opposite effects. An IGFBP-5 antisense oligodeoxynucleotide significantly decreased IGFBP-5 accumulation in conditioned media and enhanced MCF-7 cell DNA synthesis. Furthermore, this antisense oligodeoxynucleotide attenuated both antiestrogeninduced IGFBP-5 accumulation and antiestrogeninduced growth inhibition. These data demonstrate that estradiol down-regulates and ICI up-regulates an autocnne IGFBP-5 growth inhibitory pathway in MCF-7 cells and suggest that IGFBP-5 plays a role in modulation of proliferation of breast cancers by estrogens and antiestrogens. Introduction IGF3-l and IGF-ll are potent mitogens and inhibitors of apoptosis for many normal and neoplastic cell types (1). Both IGF-l and IGF-lI have high affinity for IGFBPs. To date, six IGFBPs have been characterized (reviewed in Ref. 2). These binding proteins are found in many physiological fluids and Received 5/9/96; revised 7/24/96; accepted 8/6/96. The ‘costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to mdicate this fact. 1 This work was supported by grants from the Canadian Breast Cancer Foundation (Grant 6032 to H. H.) and from the Breast Cancer Initiative Program of the National Cancer Institute of Canada (to M. P.). 2 To whom requests for reprints should be addressed. Phone: (514) 3408260, ext. 5263; Fax: (514) 340-7502. 3 The abbreviations used are: IGF, insulin-like growth factor; IGFBP, IGFbinding protein; ICI, ICI 182780; DMBA, 9,10-dimethyl-1 ,2-benzanthracene; SEPF, serum, estrogen, and phenol red free. conditioned media of a wide variety of cell types and modulate IGF bioactivity in a complex manner. Although the IGFBPs are known to influence access of lGFs to their receptors, their precise physiological roles remain unclear, and both stimulatory and inhibitory effects on cellular proliferation have been reported under various experimental conditions (3-7). The human IGFBP-5 gene is divided into four exons which span 33 kb of DNA (8). IGFBP-S was originally purified from rat serum (9), human bone (1 0), and medium conditioned by human osteoblast-like cells (1 1). IGFBP-5 has been shown to potentiate (1 0, 12) or inhibit (5) IGF action under specific experimental conditions. The different effects of IGFBP-5 observed in various experimental systems may be related to differences in posttranslational modification of IGFBP-5 (13) or to differences in extracellular matrix interactions (14). SV4O transformation provides an example of stimulation of proliferation correlated with decreased IGFBP-5 synthesis and increased cellular responsivity to IGFs (1S). Antiestrogens are widely used in breast cancer treatment, and it has been proposed that effects of these drugs on genes involved in regulation of IGF bioactivity may contribute to their antiproliferative activity (16-1 8). For example, the uterotrophic actions of tamoxifen are correlated with upregulation of IGF-l expression and down-regulation of IGFBP-3 expression, whereas the complete antiestrogen ICI (1 9), which causes uterine involution, is associated with opposite effects (20). The first example of stimulation of an autocrine growth inhibitory loop by an antiestrogen concerned tamoxifen stimulation of transforming growth factor 3 secretion (21). More recently, IGFBP-3 has been implicated in antiestrogen action (7). In this report, we describe experiments designed to evaluate the role of IGFBP-5 gene expression in the modulation of proliferation of estrogen receptor-positive breast cancer cells by estradiol and antiestrogens. Resufts Effects of ICI on IGFBP-5 Gene Expression in DMBAinduced Mammary Tumors. A prior study (1 9) described the antineoplastic activity of ICI on DMBA-induced mammary tumors. Fig. 1 illustrates the effect of ICI on the abundance of IGFBP-5 mRNA in this tumor model. Baseline expression of the IGFBP-5 gene in DMBA-induced breast tumors was stimulated approximately 2-3-fold by ICI. This motivated studies of the role of IGFBP-S in the regulation of breast cancer cell growth in vitro. Effects of Estradiol and ICI on IGFBP-5 Gene Expression in MCF-7 Breast Cancer Cells. Northern blot analysis revealed significant effects of estradiol and ICI on IGFBP-S mRNA abundance. Densitometric scanning of Northern blots revealed that IGFBP-S mRNA abundance was more than 7-fold higher in controls than in cells exposed to 1 0_b M

Activation of insulin-like growth factor I receptor-mediated pathway by ginsenoside Rg1.

Mitogen-activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells.

Ginsenoside Rg1 Exerts Estrogen-Like Activities Via Ligand-Independent Activation of ERα Pathway

Ginsenoside Rg1 facilitates neural differentiation of mouse embryonic stem cells via GR-dependent signaling pathway.

Ginsenoside Rg1 Promotes Bone Marrow Stromal Cells Proliferation Via the Activation of the Estrogen Receptor-Mediated Signaling Pathway.

Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells.

Ginsenoside Rg3 Inhibits CXCR4 Expression and Related Migrations in a Breast Cancer Cell Line.

Ginsenoside Rh2 inhibits breast cancer cell growth via<?A3B2 ACK?>ERβ-TNFα pathway

Interaction between insulin-like growth factors Ⅰ receptor and estrogen receptor induced by estradiol and insulin-like growth factors Ⅰ

Interaction Between Igf-Ir And Er Induced By E2 And Igf-I

Igfbp-Rp1 Acts As A Potential Tumor Suppressor Via the Suppression of Erk Signaling Pathway in Endometrial Cancer Cells

Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis.

Estrogenic Effects of Ginsenoside Rg1 in Endometrial Cells in Vitro Were Not Observed in Immature Cd-1 Mice or Ovariectomized Mice Model

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes

Ginsenoside Rg1 modulates PI3K/AKT pathway for enhanced osteogenesis via GPER

Ginsenoside Rh2 Suppresses Growth of Uterine Leiomyoma in Vitro and in Vivo and May Regulate ERα/c-Src/p38 MAPK Activity

Ginsenoside CK, rather than Rb1, possesses potential chemopreventive activities in human gastric cancer via regulating PI3K/AKT/NF-κB signal pathway

Ginsenoside Rg1 interferes with the progression of diabetic osteoporosis by promoting type H angiogenesis modulating vasculogenic and osteogenic coupling

A Role for Insulin-like Growth Factor Binding Protein 5 in the Antiproliferative Action of the Antiestrogen ICI 1827801

Ginsenoside Rk1 Ameliorates ER Stress-Induced Apoptosis through Directly Activating IGF-1R in Mouse Pancreatic [math]-Cells and Diabetic Pancreas

Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt